Veracyte Inc
Research Veracyte Inc (VCYT) on Bullrun: valuation model: 2.0% undervalued, market cap USD 3.54B, P/E 31.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVCYT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal2.0% undervalued
- Market capUSD 3.54B
- P/E31.2
- Financial periodQ2 2026
- RevenueUSD 150.32M
- Net incomeUSD 25.49M
- Free cash flowUSD 42.97M
- Gross margin72.2%
Valuation Snapshot
Bullrun's latest valuation model marks Veracyte Inc as 2.0% undervalued; latest market cap is USD 3.54B; P/E is 31.2.
Peer valuation comparison
Latest P/E is 31.25x versus a Healthcare sector median of 24.46x (27.8% above).
Latest P/E is 31.25x versus a United States median of 24.87x (25.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 517.15M | USD 66.40M | USD 126.63M | 70.1% | 0.82 | USD 362.58M | USD 39.65M | USD 1.31B |
| FY2024 | USD 445.76M | USD 24.10M | USD 63.81M | 66.9% | 0.31 | USD 239.09M | USD 50.74M | USD 1.18B |
| FY2023 | USD 361.05M | -USD 74.40M | USD 34.26M | 63.6% | -1.02 | USD 216.45M | USD 12.63M | USD 1.04B |
| FY2022 | USD 296.54M | -USD 36.60M | -USD 1.01M | 59.2% | -0.51 | USD 154.25M | USD 0 | USD 1.08B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.54B | 31.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.34B | 51.3 | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.08B | 127.7 | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.01B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.70B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.93B | n/a | n/a | n/a |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Veracyte Inc overvalued or undervalued?
Bullrun's valuation model currently marks Veracyte Inc as 2.0% undervalued.
What is Veracyte Inc's market cap?
Veracyte Inc's market capitalization is USD 3.54B.
What is Veracyte Inc's P/E ratio?
Veracyte Inc's price-to-earnings (P/E) ratio is 31.2.
What does Veracyte Inc do?
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc.